Swiss-Based Biotech Pops On Covid-19 Related Results

Swiss-Based Biotech Pops On Covid-19 Related Results

By: Dylan Sikes – News

Tuesday, February 23, 2021

A Swiss-based biotech firm just announced that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint. Shares of Relief Therapeutics Holding AG (OTCQB:RLFTF) were trading higher on the news.

Relief Therapeutics Holding AG is a Switzerland based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.

As mentioned earlier, traders were bullish on the news as shares traded up to a session high of $0.4267/share (+15.38%). This is a welcomed move for investors as the broader market continues its selloff.

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Tech Stock Rallies On Two Purchase Orders Announcement
$1 Million In Purchase Orders Sends Industrial Micro-Cap Higher
Illinois School District Latest of Many To Sign Contract With This Company For School Bus Safety Technology
Most Popular
FREE Newsletter Favorites

Back to Top